Click here to get this post in PDF
GLP-1s and peptides get discussed publicly as if they’re a single injectable shortcut: take the shot, watch the number drop, done.
Myra Ahmad, the physician who founded and runs Mochi Health, argues that almost every part of that story is wrong.
Ahmad trained in obesity medicine and bariatric surgery research at the University of Washington, MIT, and UCSF before founding Mochi, and she continues to see the dosing myths and dropout patterns firsthand in patients coming through the platform.
What she describes are less individual mistakes than a set of assumptions the field itself hasn’t corrected.
Myth: More Dose Means More Progress
The most common misconception is that a higher dose always means faster or more durable results.
“Standard dosing protocols assume that what works for the average patient in clinical trials will work for everyone, and that is just not true,” she has said.
“Individual differences in metabolism, body composition, and medication sensitivity mean a lot of people are on doses higher than they need.”
She’s also direct about the instinct that drives this mistake. “I worry about patients speed-running to the strongest possible medication or the highest dose without giving the lower doses a real chance,” she has said.
“Starting smaller and scaling based on your actual response is often the more sustainable path.” The data backs up why that matters: in her January 2026 MedCity News op-ed, Ahmad cited research showing roughly half of U.S. patients on GLP-1s for obesity discontinue within the first year, with most regaining the weight within the year that follows, and gastrointestinal side effects affecting an estimated 40 to 70 percent of users, largely a function of doses higher than many patients actually need.
Myth: Side Effects or Cost Mean It’s Time to Quit
Ahmad’s clearest correction is aimed at what patients do when a medication becomes uncomfortable or unaffordable.
“If a medication is causing intolerable side effects or is financially unsustainable, that is a conversation to have with your provider, not a reason to quit,” she has said.
Her proposed alternative is microdosing: starting below the standard dose and adjusting gradually based on how a specific patient responds, rather than quitting outright or pushing through at a dose the body isn’t tolerating.
Patients are already discovering this path without medical guidance. A 2025 survey found 36 percent of GLP-1 users were microdosing on their own and another 32 percent had tried it previously, with 66 percent doing so to reduce side effects and 38 percent for cost.
Ahmad’s position is that this instinct is sound, but the execution is risky without a physician involved: “done correctly, this method demands greater medical supervision, not less,” precisely because personalizing a dose introduces variables a standard protocol never has to account for.
Myth: These Drugs Only Work for Weight Loss
Ahmad also pushes back on the idea that a number on the scale is the only outcome that matters. She has pointed to patients coming in for weight management who later report their menstrual cycles returning, sometimes after years of irregular cycles tied to high BMI, occasionally opening a path to pregnancy for women who assumed that door was closed.
Extreme BMI, in either direction, is associated with abnormal cycles, and many fertility clinics decline patients above a certain BMI threshold, which means a metabolic medication is quietly doing reproductive-health work that has nothing to do with vanity metrics.
She describes tracking “non-scale victories” with the same seriousness as weight: patients returning to activities they’d given up, from keeping up with grandchildren to plane trips they’d avoided.
Some of that benefit may not be strictly weight-dependent at all. Ahmad has pointed to evidence associating GLP-1s with reduced inflammation, lower cardiovascular risk, and possible neuroprotective effects, gains a patient could retain even at a dose below the one required for maximum weight loss.
Myth: Physicians Already Have This Figured Out
The most credibility-building misconception Ahmad corrects is her own. She has been candid that she wasn’t a GLP-1 believer when Mochi launched in 2022, expecting injectable medications to be a hard sell based on how reluctant patients with rheumatoid arthritis or Crohn’s had been to start biologics. “I was just objectively wrong,” she has said.
“The lesson is that your training gives you priors, and priors can be useful, but they can also blind you to what is actually happening in front of you.”
That admission matters because it comes from someone with the clinical training to know better and still had to be corrected by the data. If a physician’s own priors can misjudge patient behavior this badly, Ahmad’s argument goes, the average prescribing pattern built on the same priors deserves the same scrutiny.
Setting the Record Straight From Inside the Prescribing Room
Most public discussion of GLP-1s comes from either enthusiastic marketing or reflexive skepticism, neither of which is grounded in a prescriber’s actual caseload.
Ahmad’s corrections carry weight because they come from building a company, Mochi Health, specifically structured to let providers dose and monitor patients individually rather than default to the standard protocol.
That combination, physician first, founder second, is what lets her say plainly which parts of the public conversation about these drugs are simply wrong.
Also read: Myra Ahmad on Why Obesity Care Has to Include Mental Health
Photo by Elena Leya on Unsplash
